Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.

Saved in:
Bibliographic Details
Title: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Authors: Jackson CG, Sharples K, Thompson PI, O'Donnell A, Robinson BA, Perez DJ, Adams J, Isaacs R, Deva S, Hinder VA, Findlay MP; Cancer Trials New Zealand, University of Auckland, Level 1, Building 505, 85 Park Road, Grafton, Auckland, New Zealand. mp.findlay@auckland.ac.nz.
Source: BMC cancer [BMC Cancer] 2014 Oct 02; Vol. 14, pp. 737. Date of Electronic Publication: 2014 Oct 02.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1471-2407
DOI:10.1186/1471-2407-14-737